Previous Article | Next Article 
Molecular and Cellular Biology, September 2000, p. 6741-6754, Vol. 20, No. 18
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Uncoupling between Phenotypic Senescence and Cell
Cycle Arrest in Aging p21-Deficient Fibroblasts
Vjekoslav
Duli
,1,*
Georges-Edouard
Beney,1
Guillaume
Frebourg,1
Linda F.
Drullinger,2 and
Gretchen H.
Stein2
Centre de Recherche en Biochimie
Macromoléculaire (CRBM)-Centre National de la Recherche
Scientifique (CNRS), 34293 Montpellier, France,1
and Department of Molecular, Cellular, and Developmental
Biology, University of Colorado, Boulder, Colorado
80309-03472
Received 17 December 1999/Returned for modification 7 February
2000/Accepted 8 June 2000
 |
ABSTRACT |
Irreversible G1 arrest in senescent human fibroblasts
is mediated by two inhibitors of cyclin-dependent kinases (Cdks),
p21Cip1/SDI1/WAF1 and p16Ink4A. To determine
the physiological and molecular events that specifically require p21,
we studied senescence in human diploid fibroblasts expressing the human
papillomavirus type 16 E6 oncogene, which confers low p21 levels via
enhanced p53 degradation. We show that in late-passage E6 cells, high
Cdk activity drives the cell cycle, but population expansion is slowed
down by crisis-like events, probably owing to defective cell cycle
checkpoints. At the end of lifespan, terminal-passage E6 cells
exhibited several aspects of the senescent phenotype and accumulated
unphosphorylated pRb and p16. However, both replication and cyclin-Cdk2
kinase activity were still not blocked, demonstrating that phenotypic
and replicative senescence are uncoupled in the absence of normal p21
levels. At this stage, E6 cells also failed to upregulate p27 and
inactivate cyclin-Cdk complexes in response to serum deprivation.
Eventually, irreversible G1 arrest occurred coincident with
inactivation of cyclin E-Cdk2 owing to association with p21. Similarly,
when p21
/
mouse embryo fibroblasts reached the end of
their lifespan, they had the appearance of senescent cells yet, in
contrast to their wild-type counterparts, they were deficient in
downregulating bromodeoxyuridine incorporation, cyclin E- and cyclin
A-Cdk2 activity, and inhibiting pRb hyperphosphorylation. These data
support the model that the critical event ensuring G1
arrest in senescence is p21-dependent Cdk inactivation, while other
aspects of senescent phenotype appear to occur independently of p21.
 |
INTRODUCTION |
Human diploid fibroblasts (HDFs)
have a finite proliferative lifespan, at the end of which they cease
irreversibly to divide and they undergo a series of phenotypic changes
that distinguish senescence from quiescence (26). These
phenotypic changes include altered morphology, increased cell volume,
expression of a neutral senescence-associated
-galactosidase
activity (SA-
-Gal), and increased production of extracellular
matrix degradative enzymes such as collagenase and stromelysin
(26, 40, 61). It is now generally accepted that two
inhibitors of cyclin-dependent kinases (Cdks), p16Ink4a
(p16) and p21Cip1/Waf1/Sdi1 (p21), whose amounts increase
with age, have an essential role in inactivating Cdks in senescent
fibroblasts (1, 24, 42, 44, 60). Cdk inactivation, in turn,
allows the accumulation of unphosphorylated retinoblastoma protein
(pRb) (59), a growth suppressor whose function is modulated
by Cdks. Unphosphorylated pRb exerts negative regulation of cell cycle
progression by forming complexes with members of the E2F transcription
factor family (23, 28).
In spite of their undisputed role in mediating senescence, the precise
contribution of each Cdk inhibitor (CKI) is not fully established. The
CKI p21 binds to and inactivates most cyclin-Cdk complexes, whereas p16
blocks cyclin D-Cdk activation by binding specifically to Cdk4 and
Cdk6, thus preventing their association with cyclin D (57).
Although several investigators proposed that both inhibitors play a
role in causing the senescent G1 arrest (1, 24),
our recent results raised the possibility that inactivation of
Cdk-cyclin complexes and subsequent G1 arrest in senescent fibroblasts is initially accomplished by p21 alone and occurs prior to
p16 accumulation (60). Therefore, we proposed that p16 is
upregulated as part of a program terminal initiated at the end of
lifespan and that it is involved in maintenance of the senescent arrest
(60). The predominant role of p21 in senescence is also
supported by results showing that specific inactivation of p21 in HDFs
bypasses senescence in spite of p16 accumulation (7).
The antiproliferative signals provoking the elevation of p21 levels in
senescent cells are thought to be generated by telomere shortening, but
the precise mechanism for this is not known. Factors that compromise
p53 activity, such as simian virus 40 large T antigen or human
papillomavirus type 16 (HPV-16) E6 oncogene, interfere with the
accumulation of p21, suggesting that the age-dependent p21 increase is
p53 dependent (5, 49, 53, 55). In this way, cellular
senescence is similar to radiation-induced cell cycle arrest, which is
also mediated by p53-dependent accumulation of p21 (18).
HDFs expressing HPV-16 E6 oncoprotein have an extended lifespan
(55), but the behavior of these cells at the end of the lifespan is not understood. For example, Filatov et al. (21) reported that replicative senescence was inactivated in HDFs expressing HPV-16 E6 and, consequently, these cells had an extended lifespan that
ended in crisis without expression of the senescent phenotype, as
measured by SA-
-Gal activity. In contrast, Bond et al.
(4) found that HDFs expressing HPV-16 E6 had an extended
lifespan that ended with arrest in a senescence-like state,
characterized by the senescent morphology and expression of SA-
-Gal
activity. Thus, conflicting outcomes were obtained in these two studies.
The mechanism for the senescent cell cycle arrest in E6 cells is also
not well defined. Bond et al. (4) suggested that a
senescence-associated increase in p21 does not occur in E6 cells because senescent E6 cells have less p21 than wild-type controls and
that the senescence-like cell cycle arrest of E6 cells is probably
mediated by the increase in p16 that occurs at the end of lifespan.
Although those experiments indicated clearly that senescent E6 cells
have less p21 than wild-type controls, they could not show directly
whether there is an age-associated increase in p21 in E6 cells because
the HDFs were grown to near senescence before they were transfected
with HPV-16 E6. Moreover, the effect of p16 on the formation of cyclin
D1-Cdk4 and -Cdk6 complexes was not assessed, thereby leaving
unanswered the question of whether elevated p16 is sufficient to
mediate the senescence-like cell cycle arrest of E6 cells.
Finally, our previous results indicated that elevated p16, increased
cell volume, and expression of SA-
-Gal activity occur primarily
after the senescent cell cycle arrest is initiated in wild-type HDFs,
suggesting that these senescence-associated changes might be dependent
on prior elevation of p21 and initiation of the senescent cell cycle
arrest (60). Likewise, Millis et al. (40) showed
that there is a dramatic increase in the expression of collagenase at
the very end of the lifespan in HDFs, suggesting that fibroblast
functions are also altered in response to the senescent cell cycle
arrest. These results raised the question of whether
senescence-associated changes can take place in E6 cells independently
of a high p21-mediated senescent cell cycle arrest. Since our work was
submitted, Wei and Sedivy (65) reported that
p21
/
HDFs express SA-
-Gal activity while remaining
replicative, thereby supporting the hypothesis that the senescence
program is not attenuated by downregulation of p21.
We have studied the cell cycle machinery and the phenotype of E6 cells
throughout their lifespan to answer the questions raised above. We have
also studied wild-type and p21
/
mouse embryo
fibroblasts (MEFs) to test our hypotheses further. Our results show
that a single population of E6 cells can exhibit both crisis and
senescence and demonstrate how the cell cycle machinery is affected in
each of these stages, with several surprising results. First, the small
amount of p21 in E6 cells plays a crucial role in mediating their
senescent cell cycle arrest. Second, in terminal passage E6 cultures
that are not yet senescent the cyclin E-Cdk2 and cyclin A-Cdk2 kinase
activities are high and the cells are replicative in spite of a lack of
pRb hyperphosphorylation. Third, terminal-passage E6 cells express the
senescence-associated phenotype even though the population is still
replicative. Fourth, in contrast to wild-type cells and in spite of
high p16 amounts, late-passage and senescence-like p21
/
MEFs are not able to block DNA synthesis.
 |
MATERIALS AND METHODS |
Cell culture and markers of the senescence phenotype.
IMR90
HDFs from the fetal lung were cultured as described earlier
(60). DNA synthesis (percent labeled nuclei) was determined by autoradiography of cells labeled with [3H]thymidine
for 24 h. The relative cell volume was calculated from the volume
of the pellet formed by 4 × 106 freshly trypsinized
cells centrifuged at 100 × g for 5 min. The results
were consistent with the cell volume calculated on the basis of cell
diameter in a hemacytometer. SA-
-Gal activity was determined by the
method of Dimri et al. (16). Steady-state amounts of p21,
collagenase (MMP-1), and
-actin mRNAs were determined by Northern
blotting with cDNA probes, as previously described (17, 40).
IMR90-E6 cells, prepared by retroviral transfer of the HPV-16 E6
oncogene in the PLXSN vector, were provided generously by Jerry Shay
(The University of Texas SW Medical Center, Dallas) (55).
These cells were passaged according to the same protocol used for
wild-type HDFs. MEFs from p21
/
mice (8) were
provided generously by Tyler Jacks (Massachusetts Institute of
Technology, Cambridge).
Immunofluorescence microscopy.
The conditions for the cell
fixation, double-immunolabeling, and mounting were as described
previously (19). Immunofluorescence and phase-contrast
photomicrographs were image captured, and a composite generated using
Adobe Macintosh Photoshop or Microsoft Powerpoint software. For the
time-lapse microscopy experiments (Hamamatsu software), cells were kept
in a temperature- and CO2-controlled chamber.
Immunoprecipitations, immunoblot analysis, and antibodies.
Preparation of whole-cell lysates from frozen cell pellets, conditions
for immunoprecipitation, histone H1 kinase assays, and immunoblotting
have been described previously (17). For p21 or p27
depletion, total cell extracts (usually 100 to 150 µg) were incubated
with saturating amounts of p21- and p27-specific antibodies, whereas
mock samples were incubated with protein A-Sepharose beads only. The
resulting supernatants were analyzed by immunoblotting and/or used for
further immunoprecipitation with cyclin-specific antibodies as
described previously (60). Proteins were visualized by
enhanced chemiluminescence (ECL; Amersham) and quantitated by
densitometry using Adobe Photoshop software. In some cases the same
immunoprecipitates were used both for the determination of histone H1
kinase activity and for the immunoblot detection of various components.
This was accomplished by a controlled partial transfer of 12% gels
following sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). The resulting membrane was then used for immunoblot
analysis using the indicated antibodies, whereas the gel was stained
with Coomassie blue and dried, and the histone H1 bands were excised
and counted by the Cerenkov method as described previously
(17).
The round mitotic-cell-like cells from late passage E6 cultures
(population-doubling numbers [PDs] of 77 and 78) were harvested
by
vigorous pipetting and pelleted by low-speed centrifugation.
The
equivalent of 20 100-mm dishes was needed for approximately
200 µg of
total cell
extracts.
Most of the primary antibodies used in this study were the same as
described previously (
19,
60). Anti-cyclin D2 antibody
was
from Gilles Ponzio (INSERM, Nice, France) (
48), anti-Skp2
antibody was from Thierry Lorca (CRBM, Montpellier, France), and
anti-HPV16-E6 antibody was from Martin Mueller (Heidelberg, Germany).
In addition, commercially available antibodies used were anti-p27
(sc-528), anti-p53 (DO-1, sc-126), anti-HPV16-E6 (C-19, sc-1583),
and
anti-p107 (C-18, SC-318) from Santa-Cruz Biotechnology and
anti-phospho-pRb (Ser780) from MBL, Watertown, Mass. Secondary
antibodies were anti-mouse and anti-rabbit immunoglobulin G-horseradish
peroxidase conjugates
(Promega).
 |
RESULTS |
Replication-associated events do not decrease in late-passage HDFs
expressing HPV-16 E6 oncogene.
To understand whether senescence is
possible in the absence of high amounts of p21 and, if so, what the
alternative mechanisms are whereby the cell accomplishes the cell cycle
arrest, we studied the in vitro aging of HDFs (IMR-90) expressing the
HPV-16 E6 oncogene (55). Since senescence is a dynamic
process, which includes both a block of replication events and numerous
morphological and biochemical changes conferring the senescence
phenotype, we first sought to define different stages during the
cellular aging of E6 cells compared with wild-type HDFs. We measured
several parameters, including [3H]thymidine
incorporation, serum response, SA-
-Gal staining, cell volume, and
population density that could help in determining both the onset of
senescence, defined as an irreversible cell cycle arrest in
G1 (<5% labeled nuclei) and the appearance of the
senescence phenotype. In wild-type cells, the end of lifespan (EOL)
stage, i.e., the stage when the population undergoes no further
expansion, coincides with cell cycle arrest, but a complete expression
of the senescence phenotype, characterized by strong SA-
-Gal
staining (16), a fivefold increase in cell volume, and
maximal p16 elevation, is achieved more slowly with kinetics that
suggest that these changes occur after the senescent cell cycle arrest
is achieved (60). We termed this stage "late senescence" (Fig. 1).

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 1.
In vitro aging of wild-type and E6 HDFs. (A) Growth
curves (PD versus time) for wild-type HDF (WT) and E6 cells were
aligned at the EOL, defined as the time when no further PDs were
achieved. The percentages of quiescent or senescent cells able to
synthesize DNA after serum stimulation were measured by autoradiography
of cells labeled with [3H]thymidine for 24 h. EOL
coincided with senescent cell cycle arrest (SEN) in wild-type HDFs but
not in E6 cells. Terminal-passage (T.p.) E6 cells at EOL have distinct
characteristics that are described in the text. EOL, no further
population doublings; SEN, senescence; , irreversible G1
arrest; L.S., late senescent stage, characterized by elevated p16 and
positive SA- -Gal staining. (B) Relative cell size and SA- -Gal
staining (16) of the same populations as in panel A. (C)
Northern blot analysis showing mRNA levels of p21, collagenase, and
-actin in asynchronous early-passage (EP) and terminal-passage (TP)
wild-type and E6 HDFs. The amount of p21 mRNA normalized to -actin
mRNA increased six- to sevenfold in terminal-passage cells versus
early-passage cells for both wild-type and E6 cells, even though E6
cells have much lower amounts of p21 mRNA overall.
|
|
Even though most growth properties of early-passage E6 cells did not
differ significantly from their wild-type counterparts,
late-passage
(PD > 60) E6 cells exhibited several characteristics
that
suggested a greatly perturbed senescence process (Fig.
1).
First,
late-passage E6 cells became more replicative in response
to serum
stimulation, in contrast to the decreased replicative
response of
comparably passaged wild-type cells. Second, E6 cells
continued to
replicate even in terminal-passage cultures, i.e.,
the point at which
no more population doublings could be achieved.
Third, terminal-passage
E6 cells acquired several phenotypic characteristics
of senescent
wild-type cells, such as increased cell volume, SA-

-Gal
accumulation and increased expression of collagenase (Fig.
1).
These
results demonstrated that cell cycle arrest and the senescence-related
phenotype are not necessarily coupled. Eventually, and at a somewhat
variable PD (PDs of 79 to 87), E6 cells ceased to replicate, a
finding
which was in agreement with the results published earlier
by several
groups (
4,
10).
Our observations raised two questions. First, how can sustained
replication take place at the same time as decreasing population
expansion? Second, what are the mechanisms whereby senescent E6
cells
finally achieve cell cycle
arrest?
Abortive mitoses increase in aging E6 cells.
Late-passage E6
cells exhibited both DNA replication (Fig. 1A) and an accumulation of
large, round, mitotic-cell-like cells, whose numbers increased
significantly toward the EOL, in parallel with a decrease of the
population expansion. The fate of these cells was determined by using
time-lapse microscopy, a technique that enables continuous viewing of
individual cells. By comparing two different late passage E6
populations (PDs of 69 and 78), we found that the number of mitotic
cells undergoing successful cytokinesis decreased dramatically as the
cells approached their terminal passage. Instead, an increasing number
of cells underwent: (i) mitosis without cytokinesis, resulting in
binucleate cells; (ii) transient fragmentation followed by resealing,
giving rise to cells with fragmented nuclei; and (iii) cell death,
presumably by apoptosis (Fig. 2A and B). This
mitotic-cell-like state often lasted for several hours, during which
the cell exhibited rapid mobility and changing of shape (Fig. 2A, lower
panel). Microscopic analysis of Hoechst- or orcein-stained cells
indicated that most mitotic cells were in a metaphase-like stage (data
not shown). In addition, the later-passage E6 population became
increasingly aneuploid, presumably owing to increasing endoreplication
events in the absence of the G2/M checkpoint (Fig. 2C)
(21, 67). In contrast to late-passage E6 cells, in
late-passage wild-type HDF populations virtually all mitotic cells
completed cytokinesis, and very few binucleate cells could be observed
(data not shown).

View larger version (55K):
[in this window]
[in a new window]
|
FIG. 2.
Increasing abortive mitoses in old E6 populations. (A)
In the upper panel are shown the fates of individual mitotic cells from
two different old E6 populations (PD 69 and PD 78) monitored at 5-min
intervals by time-lapse microscopy. Representative micrographs of
mitoses giving rise to normal (a), binucleate (b), multinucleate (c),
and apoptotic (d) cells are shown. All micrographs were taken at the
same magnification. Hoechst 33258-stained micrographs (corresponding to
these situations) were taken from formaldehyde-fixed cells. In the
lower panel, a more-detailed sequence of the cell presented in the c
panel showing rapid changing of shape and position is presented. Cell
movements were obvious even on a "real-time" scale. (B)
Quantitative analysis of time-lapse microscopy-acquired data showing
different outcomes of mitotic events observed in old E6 populations.
Norm, normal; w/o cytok, without cytokinesis; Frag, fragmented; Apo,
apoptotic. Note that aberrant mitoses and cell death were also
frequently observed in the early-old E6 cells (PD 69). (C)
Fluorescence-activated cell sorter (FACS) analysis of old (PD 78) E6
cells. The cells were serum deprived for 48 h to show the absence
of cell cycle arrest. (D) Western blot and histone H1 kinase analysis
of cyclin B1 immunoprecipitates (I.P.) isolated from lysates prepared
from whole-cell population (Tot) and round mitotic (Mit) E6 cells (PD
77). Floating cells corresponded to the mitotic population examined in
panels A and B. Total cell extracts were also analyzed for pRb, cyclin
A, cyclin E, and cyclin B1 content, as indicated.
|
|
To analyze further the actual cell cycle stage of the round cells,
their extracts were assayed for cyclin B1-associated kinase
activity
and for the presence of several cell cycle regulators.
Indeed, when
compared to the total cell population (Tot), the
round cells
(mitotic-Mit) contained extremely high cyclin B1-associated
kinase
activity, and all Cdk1 (cyclin B1-associated and total)
was in its
fully dephosphorylated/active state (Fig.
2D). Importantly,
the
presence of hyperphosphorylated pRb suggested that the events
leading
to aberrant mitoses occurred during a stage of the lifespan
when the
Cdks were fully active. Thus, these results provide an
explanation for
the slowdown and cessation of population doublings
in late-passage E6
populations in the absence of cell cycle
arrest.
"Uncoupling" between pRb phosphorylation, G1
arrest, and cyclin-Cdk2 activity in terminal-passage E6 cells.
As
mentioned earlier, the accumulation of underphosphorylated pRb in
wild-type senescent cells occurs concomitantly with p21-mediated inactivation of cyclin E-Cdk2 kinase and with increased association of
p21 with cyclin D1-Cdk complexes, such that all cyclin D1-Cdk6 and
almost all cyclin D1-Cdk4 complexes are p21 bound (17, 59, 60). Therefore, one would not expect a comparable inhibition of
p21-deficient E6 cells at the EOL. The presence of hyperphosphorylated pRb in late-passage E6 cells at the EOL stage (Fig. 2D) was in agreement with this expectation and with their lack of cell cycle arrest as measured by continued DNA synthesis and mitosis (Fig. 1A and
2A). However, after EOL, the terminal-passage E6 cells started to
accumulate underphosphorylated pRb (Fig. 3A), suggesting that cyclin-Cdk complexes were being inactivated. To test this hypothesis directly, we examined the cyclin E- and cyclin A-associated kinase activities in immunoprecipitates isolated from cell extracts prepared from wild-type and E6 cells at the indicated stages. In
addition, total cyclin and Cdk contents were assessed by Western blot
analysis. The results presented in Fig. 3B revealed several important
findings.

View larger version (62K):
[in this window]
[in a new window]
|
FIG. 3.
Cyclin-Cdk2 inactivation is uncoupled from pRb
dephosphorylation in senescing E6 cells. (A) Western blot analysis of
pRb, p107, and P-S780 in total cell lysates prepared from early-passage
(EP), late-passage (LPa), terminal-passage (TPa), and two senescent (Sa
and Sb) populations of E6-expressing HDFs that were serum starved
(lanes 0) or serum stimulated for 16 h (lanes 16). P-S780 denotes
an antibody directed against phosphoserine 780 of pRb, which is
specifically phosphorylated by cyclin D1 (30). (B) Histone
H1 kinase activity and Western blot analysis of cyclin E and cyclin A
immunocomplexes from wild-type HDFs and E6 cells. Cyclin E and cyclin A
immunoprecipitates, isolated from the designated cell extracts, were
assayed for their kinase activities using histone H1 as a substrate and
then subjected to SDS-PAGE. Proteins were partially transferred to
polyvinylidene difluoride (PVDF) membrane and analyzed by Western blot
for their cyclin and Cdk contents. The remaining gel was subjected to
autoradiography. Cell lysates were prepared from the following
wild-type (W.T.) or E6 cell populations: wild type, early-passage (PD
27.5), senescent (PD 76), and late senescent (PD 78); E6, early-passage
(PD 45), late passage (LPa; PD 74.5), terminal passage (TPa; PD 83),
and three different senescent populations designated Sa (PD 87), Sb (PD
80), and Sc (PD 79). (C and D) Western blot analysis of designated cell
extracts using anti-p27 and anti-Skp2 antibodies. As a positive control
for Skp2, HDFs expressing HPV E7 oncogene and HeLa cells were used.
|
|
Terminal-passage E6 cells contained very high cyclin E- and cyclin
A-associated kinase activities in both serum-starved and
serum-stimulated cells and were actively engaged in DNA synthesis
under
both conditions (24 and 28% [
3H]thymidine-labeled
nuclei, respectively). Moreover, the levels
of p107, the pRb-related
pocket protein whose protein amounts
and phosphorylation by Cdks
greatly increase during G
1/S-phase
progression (
3,
66), were highly upregulated even in the
absence of serum (Fig.
3A). These results were very surprising
for three reasons. First, they
indicate that there is a dramatic
loss of serum regulation in
terminal-passage E6 cells. Second,
high cyclin E- and cyclin
A-associated kinase activities are at
odds with the strongly diminished
hyperphosphorylation of pRb
in these cells, implying that pRb
phosphorylation is blocked before
the inactivation of cyclin-Cdk2
complexes. Third, since the cells
were able to initiate replication
events and synthesize DNA in
the presence of underphosphorylated pRb,
these results suggest
that at the end of lifespan, E6 cells experience
an uncoupling
between the pRb pathway (but not the p107 pathway) and
the replication
machinery. A similar effect is seen to a lesser degree
in late-passage
E6 cells when pRb hyperphosphorylation is decreased
even though
cyclin E- and A-Cdk2 activity is high. However, when E6
cells
eventually became senescent, both cyclin E- and cyclin
A-associated
kinases had low activity, although their inactivation was
not
as efficient as in wild-type cells. Moreover, p107 protein amounts
in these cells are comparable to those of quiescent young cells
(Fig.
3A). Thus, terminal-passage E6 cells revealed the unexpected
result
that DNA synthesis and high cyclin-Cdk2 activity are uncoupled
from pRb
hyperphosphorylation, whereas senescent E6 cells revealed
that their
cell cycle arrest occurred in conjunction with reduced
cyclin-Cdk2
activity in spite of their low amounts of p21 and
p27.
The lack of cyclin E- and A-Cdk2 inactivation in serum-deprived
terminal-passage E6 cells was unexpected because p27
Kip1,
rather than p21, is usually responsible for Cdk inactivation
in
serum-starved cells (
57). However, in contrast to early-
and
late-passage E6 cells, terminal-passage E6 cells fail to upregulate
p27
when serum-deprived (Fig.
3C). Recently, p45
Skp2 was shown
to be the substrate recognition subunit of the ubiquitin-protein
ligase
that targets p27 for degradation (
13,
62). Moreover,
when
overexpressed, p45
Skp2 prevented exit from the cell cycle
upon serum withdrawal (
69).
Because this mimicked the
behavior of terminal-passage E6 cells,
we investigated whether
p45
Skp2 overexpression might be responsible for the lack of
p27 in these
cells. Our data indicate that there is no significant
difference
in the amount of p45
Skp2 in early-, late-, and
terminal-passage E6 cells, suggesting that
a simple increase in
p45
Skp2 is not the mechanism involved (Fig.
3D). Note that
there were
high Skp2 levels in late-passage E6 cells, as well as in
tumor-derived
HeLa cells and in HDF-expressing HPV-E7 oncoprotein.
Interestingly,
these experiments revealed that both wild-type and E6
cells have
greatly reduced amounts of both p45
Skp2 and p27
when they are senescent. These results suggest that,
at senescence,
factors other than p45
Skp2 promoted degradation are
responsible for the low amount of p27
in both serum-deprived and
serum-stimulated cells. On the other
hand, decreased
p45
Skp2 in senescent cells might play a role in the
accumulation of p21
and cyclin D1 because Yu et al. found that
inhibition of human
p19
Skp1-p45
Skp2-CUL-1
complexes led to an increase of p21 and cyclin D1, while
having no
effect on amount of p27 (
68).
Cell cycle arrest in senescent E6 cells is mediated by
p21-dependent cyclin E inactivation.
The results showing
inactivation of cyclin E-Cdk2 and irreversible cell cycle arrest in
senescent E6 cells raised several questions regarding the mechanism
underlying these events. Since the presence of hyperphosphorylated Cdk2
in cyclin E complexes excluded inactivation of Cdk-activating kinase as
a mechanism for decreased cyclin E-Cdk2 activity (Fig. 3B), we
predicted that their inactivation could be mediated by CKIs. However,
as shown in Fig. 4A, although late-passage and senescent
E6 cells contained somewhat increased p21 levels, these were still very
low compared to wild-type cells and were not compensated for by p27
upregulation.

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 4.
Cyclin E-Cdk2 inactivation in senescing E6 fibroblasts
is p21 dependent. (A) Western blot analysis of total cell extracts
prepared from designated cell populations described in the legend for
Fig. 3, except for late-passage E6 cells (LPb; PD 79). (B) Western blot
analysis of p21 immunoprecipitates isolated from the extracts prepared
from senescent wild-type (WT), serum-starved (0 h) and serum-stimulated
(16 h) early-passage (EP; PD 45), and stimulated (16 h) senescent (S)
E6 cells. (C) p21 immunodepletion experiments. Cell extracts from serum
starved (0 h) and serum stimulated (16 h) early-passage (EP; PD 45),
and stimulated (16 h) senescent (S; PD 79 + PD 80) E6 cells were
depleted for p21 by using specific antibodies. Mock-treated extracts
are designated " ". Following depletion, supernatants were tested
for immunodepletion efficiency (not shown) and the presence of cyclin
E. Cyclin E complexes (cyc E I.P.) were precipitated from all
supernatants, and the Cdk2 content was determined by Western blotting
using anti-PSTAIRE antibody. In addition, the same immunoprecipitates
were tested for histone H1 kinase activity (H1 kinase).
|
|
To determine whether the low amount of p21 in senescent E6 cells could
be responsible for inactivation of cyclin E-Cdk2, we
examined the
effect of complete removal of p21-containing complexes
by
immunoprecipitation (Fig.
4C). In early-passage E6 cells, as
expected,
there was no effect of p21 depletion on either the amount
of cyclin
E-Cdk2 or its activity. In contrast, in serum-stimulated
senescent E6
cells, where the cells have only one-third as much
cyclin E-associated
kinase activity as in early passage cells,
p21 depletion removed the
vast majority of the cyclin E-associated
Cdk2. As seen previously in
wild-type HDFs, only p21-free cyclin
E-Cdk2 complexes have activity
(
60). Taken together, these data
indicate that the majority
of the cyclin E-Cdk2 complexes in senescent
E6 cells are inhibited
owing to their association with p21. The
related CKI p27 may also play
a modest role because a smaller
fraction of cyclin E-associated Cdk2 is
removed by p27 depletion
(data not shown). Thus, our results strongly
suggest that increasing
association with p21 is predominantly
responsible for inactivation
of cyclin E-Cdk2 kinase and cell cycle
arrest in senescent E6
cells.
In contrast to the continued abundance of cyclin E-Cdk2 complexes in
senescent E6 cells, there is a dramatic decrease in the
amount of
cyclin A and therefore of cyclin A-Cdk2 complexes in
these cells (Fig.
3B). Moreover, p21 and p27 immunodepletion did
not significantly affect
the amount of cyclin A-Cdk complexes
in serum-stimulated senescent E6
cells (data not shown). These
results imply that in senescent E6 cells,
as in senescent wild-type
HDFs, cyclin A-associated kinase activity is
reduced primarily
through decreased complex
formation.
Accumulation of underphosphorylated pRb correlates with increasing
p21-cyclin D1-Cdk association.
Even though Cdk-dependent pRb
phosphorylation takes place throughout the cell cycle, it is widely
accepted that pRb is initially phosphorylated at mid-G1 by
cyclin D-Cdk4 and cyclin D-Cdk6 complexes (cyclin D-Cdk4/Cdk6
complexes) (25, 48). Consequently, the accumulation of
underphosphorylated pRb in terminal-passage E6 cells containing high
cyclin E- and cyclin A-associated kinase activities might occur because
prior phosphorylation of pRb by cyclin D-Cdk complexes is reduced.
Indeed, previous studies had suggested that a lack of cyclin D-Cdk
complex formation owing to accumulation of p16 might be the mechanism
for the senescent cell cycle arrest in p21-deficient E6 cells
(4). To determine whether cyclin D1-dependent pRb
phosphorylation occurred in terminal-passage and senescent E6 cells, we
analyzed the phosphorylation of pRb on Ser780, a site known to be
phosphorylated specifically by cyclin D-Cdk4/Cdk6 complexes
(30). Our data indicate that phosphorylation at pRb-Ser780
is greatly reduced in terminal-passage E6 cells and is negligible in
senescent E6 cells (Fig. 5A; cf. Fig. 3A). In all of our
experiments, phosphorylation of pRb-Ser780 and hyperphosphorylation of
pRb changed coordinately, a result consistent with the idea that cyclin
D-Cdk4/Cdk6 complex phosphorylation of Ser780 may be necessary for
subsequent hyperphosphorylation of pRb.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
Accumulation of underphosphorylated Rb correlates with
increasing p21-cyclin D1-Cdk association in late-passage and senescent
wild-type and E6 cells. (A) Western blot analysis of extracts prepared
from designated cell populations (see legend for Fig. 3) using a
pRb-specific antibody (see above) and the polyclonal antibody directed
against phosphoserine 780 of pRb which is specifically phosphorylated
by cyclin D1 (S-780 [30]). Arrows show a band
corresponding to pRb phosphorylated on S-780 and a 100-kDa band (?),
recognized by the same antibody, that accumulates in late senescent
HDFs. (B and C) Western blot analysis of p16 (above) and cyclin D1
(below) immunoprecipitates isolated from the indicated cell extracts
(see legend to Fig. 3). The resulting immunoprecipitates were
electrophoresed by SDS-12% PAGE, transferred onto PVDF membranes, and
analyzed for the indicated proteins using specific antibodies. The
black dot indicates the Cdk6-specific band. pRb pattern corresponding
to LPa cells is shown in Fig. 3A. (D) CKI immunodepletion experiment.
The indicated cell extracts were immunodepleted for p21 and p27, and
the resulting immunoprecipitates [CKI I.P. (pellet)] were analyzed
for the presence of Cdk6 and Cdk4, respectively. After immunodepletion,
cyclin D1 immunoprecipitates were isolated from supernatants (Sup), and
their content was assessed by Western blotting. A " " denotes
mock-treated extracts. Arrows indicate weak Cdk6-specific bands. EP,
early-passage E6 cells; TP, terminal-passage E6 cells; S, senescent E6
cells.
|
|
Phosphorylation of pRb-Ser780 was strongly diminished in terminal
passage E6 cells and completely lacking in senescent E6
cells (Fig.
5A), suggesting that either the total amount or the
kinase activity of
the cyclin D1-Cdk complexes was reduced in
these cells (
1,
4,
24). To address this question, we analyzed
both p16 and cyclin D1
immunoprecipitates isolated from extracts
prepared at different life
stages of wild-type and E6 cells. Our
results show that p16 and
p16-Cdk4/Cdk6 complexes increased in
terminal-passage and senescent E6
cells, albeit to a lesser extent
than in the wild-type cells (Fig.
5B).
To test the effect of this
increase on the formation of cyclin
D1-Cdk4/Cdk6 complexes, we
analyzed cyclin D1 immunoprecipitates from
different lifetime
stages of E6 cells (Fig.
5C and D). Early-passage E6
cells have
fewer cyclin D1-Cdk4/Cdk6 complexes than the wild-type
cells,
which is consistent with the role of p21 in stabilizing cyclin
D1-Cdk4/Cdk6 complexes. Overall, late-passage, terminal-passage,
and
senescent E6 cells have reduced amounts of cyclin D1-Cdk4/Cdk6
complexes, but the reduction is <50% for cyclin D1-Cdk4. Therefore,
p16 appears to make a contribution to the senescent cell cycle
arrest
in senescent E6 cells but is not sufficient to account
for the lack of
cyclin D1-mediated phosphorylation of
pRb.
Since we have shown previously that the accumulation of
underphosphorylated pRb in senescent wild-type cells occurred when
virtually all cyclin D1-Cdk complexes became associated with p21
(
60), we examined the cyclin D1 immunoprecipitates from E6
cells
for the presence of p21 and p27. These results showed that p21,
though virtually absent in early-passage cells, was readily detected
in
cyclin D1 immunoprecipitates from terminal-passage and senescent
cells
(Fig.
5C). By contrast, the presence of p27 in cyclin D1-Cdk
immunoprecipitates was strongly diminished in terminal-passage
and
senescent E6 cells. Thus, the increasing association between
cyclin
D1-Cdk complexes and p21 correlated well with the accumulation
of
underphosphorylated pRb and pRb-Ser780 shown in Fig.
3A and
5A.
Finally, to assess the relative contribution of p21 versus p27 in
associating with cyclin D1-Cdk4/Cdk6 complexes, we analyzed
cyclin D1
immunoprecipitates after immunodepletion of p21 or p27
(Fig.
5D). These
experiments showed that in early-passage cells
both Cdk4 and Cdk6 were
readily detected in p27 immunoprecipitates
but that in terminal-passage
and senescent cells these Cdks were
predominantly associated with p21
(Fig.
5D, pellet). Consistent
with this, p21 depletion removed
progressively more cyclin D1-Cdk4/Cdk6
complexes from terminal-passage
and senescent E6 cells than from
early-passage cells, whereas the
proportion of the complexes associated
with p27 decreased or remained
the same. Thus, the diminished
phosphorylation of pRb and pRb-Ser780 in
terminal-passage and
senescent E6 cells occurs in conjunction with
increased binding
of p21 to cyclin D1-Cdk4/Cdk6 complexes, together
with continued
binding of p27, in spite of the fact that both of these
CKIs are
present at low levels in these
populations.
In summary, we suggest that the lack of pRb phosphorylation
in terminal-passage and senescent E6 cells is a consequence of
both downregulation of cyclin D1-Cdk4/Cdk6 complex formation by
p16 and
increasing p21-mediated cyclin D1-Cdk4/Cdk6 complex inactivation.
Because cyclin E-Cdk2 and cyclin A-Cdk2 activities are not
concomitantly
downregulated in terminal-passage cells, these cells
exhibited
the surprising uncoupling of pRb phosphorylation and cell
cycle
progression described above. In other words, pRb
hyperphosphorylation
depends on cyclin D1-dependent hypophosphorylation
(
20,
25),
which does not occur in terminal-passage E6 cells,
whereas cyclin
E-Cdk2 and cyclin A-Cdk2 kinase activities persist in
those cells
and are sufficient to allow them to progress to S
phase.
Evidence for p53-dependent p21 accumulation.
Although modest
compared to wild-type cells, the age-dependent increase of p21 in E6
cells was reproducible and was also observed by others (4).
Western blot analysis confirmed that in most cases p21 upregulation
coincided with a small but detectable p53 increase (Fig.
6A and results not shown). These results suggested that
p53-dependent accumulation of p21 might be essential for the onset of
events leading to cell cycle arrest. To test this hypothesis, we
determined p53 levels in a late-passage E6 population (LPc; PD 77)
exhibiting aberrant mitoses (Fig. 2). We found that even though the
population as a whole contained modestly elevated p53 levels (and p21
[data not shown]), no p53 was detectable in the cells undergoing
aberrant mitotic events (Fig. 6B), a result consistent with the notion
that some p53 is needed to avoid this outcome.

View larger version (104K):
[in this window]
[in a new window]
|
FIG. 6.
Increase of p21 in senescent E6 correlates with rise of
p53. (A) Western blot analysis of cell lysates prepared from
early-passage (EP) and senescent (S) wild-type HDFs and from
early-passage, terminal-passage (TPb) and senescent (Sa and Sc) E6
cells. Where indicated, the cells were serum starved (lanes 0) or serum
stimulated for 16 h (lanes 16). A prolonged ECL exposure was used
to detect p53, whose level varies among different terminal passage and
senescent E6 populations. In the presented Sc extract, the p53 band was
too faint to be seen in the photograph but it is clearly detectable on
the original fluorograph, as well as in other Western blots. (B)
Absence of p53 in aberrant mitotic cells shown in Fig. 2. Western blot
analysis of cell lysates prepared from senescent wild-type (PD 76),
early-passage (PD 42), and late-passage (LPc; PD 77) cells. M, round
mitotic cells; T, total cell population. (C) Age-related chromosome
condensation in E6 cells is p21 and p53 dependent. Indirect
immunofluorescence of exponentially growing populations of
early-passage and senescent E6 cells. The cells were fixed in
paraformaldehyde and then simultaneously stained with rabbit polyclonal
anti-p21 and anti-BrdU (Br; early passage) or monoclonal anti-p53
antibodies (senescent; Sen). The nuclei were counterstained with
Hoechst 33258 (Hoe). Arrows indicate a p53-expressing cell.
|
|
These observations raised several questions regarding the origin of
p53-containing E6 cells. Although p53 amounts were still
low in
senescent E6 populations, it is possible that a population
of the cells
with the lowest level of E6 expression became enriched
by positive
selection. Unfortunately, we could not test this possibility
directly
because we could not detect E6 protein with several available
anti-E6
antibodies. However, we did examine the expression of
p53 and p21 in
individual E6 cells by indirect immunofluorescence.
These data
indicated that a senescent E6 population contained
a very small
population of cells (<5%) that was labeled strongly
both by anti-p21
and anti-p53 antibody (Fig.
6C). These cells
were also unique in having
a "speckled" distribution of DNA, as
revealed by Hoechst staining.
This speckled distribution of DNA
is characteristic of wild-type
senescent HDFs (data not shown)
and may reflect a senescence-associated
condensation of chromatin.
Thus, these data suggest that at most a tiny
minority of senescent
E6 cells may have had unusually low E6
expression. In addition
to the lack of speckled nuclei, senescent E6
populations have
other features that further distinguish them from
senescent wild-type
cells (see
below).
Absence of senescence-dependent increase of cyclin D2-Cdk in E6
cells.
While analyzing pRb phosphorylation in E6 cells, we
observed that senescent E6 cells failed to accumulate a presumably
pRb-related phosphoprotein (ca. 100 kDa), which was recognized by
anti-pRbS780 antibody and which increased dramatically in late
senescent wild-type cells (Fig. 5A). Since this antibody was raised
against a cyclin D-specific phospho-pRb peptide, we speculated that
this protein might be a potential substrate of D-type cyclin-Cdk
complexes. Given our results suggesting that cyclin D1-Cdk complexes in
wild-type late senescent cells are inactive, we examined protein levels of cyclin D2, a D-type cyclin recently found to increase in senescent cells (39, 56). Interestingly, we found that cyclin D2
accumulated very strongly in late senescent wild-type cells, whereas it
increased to a much smaller extent in senescent E6 cells (Fig.
7A). In addition, Western blot analysis of cyclin D
immunoprecipitates showed a specific increase of cyclin D2-Cdk4
complexes in late senescent HDFs (Fig. 7B). Even though these results
do not show that the 100-kDa putative pRb-related protein is indeed a
cyclin D2-Cdk4 substrate, they suggest that this is a possibility. They
also demonstrate that E6 cells do not attain the wild-type senescent stage characterized by elevated cyclin D2 levels. Thus, cyclin D2 may
specifically play a role during the late stages of senescence.

View larger version (56K):
[in this window]
[in a new window]
|
FIG. 7.
Cyclin D2/Cdk4 complexes accumulate in senescent
wild-type but not E6 cells. (A) Western blot analysis of cell lysates
prepared from indicated cell extracts which are described in the legend
for Fig. 3. Note that anti-cyclin D2 antibody (47)
cross-reacts with cyclin D1. (B) Western blot analysis of cyclin D1 and
cyclin D2 immunoprecipitates isolated from early-passage (EP),
senescent (S), and late senescent (LS) wild-type HDFs. Cyclin D1 and
cyclin D2 were sequentially immunoprecipitated from the same extracts.
Cyclin D1-specific band visible in cyclin D2 IP is either a
"leftover" from cyclin D1 immunoprecipitation or it results from a
cross-reaction.
|
|
Terminal-passage p21
/
MEFs are deficient in
G1 arrest.
To test further the idea that p21 is
required for inactivation of Cdks, inhibition of pRb phosphorylation,
and prevention of DNA synthesis in senescent cells, we analyzed cell
cycle regulation in fibroblasts derived from wild-type and p21
nullizygous mouse embryos (p21
/
MEFs
[8]). The starting cultures of both wild-type and
p21
/
MEFs (p5 and p6, respectively) consisted of small,
vigorously proliferating cells of rather uniform size. With increasing
passage, the wild-type cultures gradually became enriched for large,
often binucleated cells, and strongly reduced bromodeoxyuridine (BrdU) incorporation at passage 9 (Fig. 8C and D), with no
outgrowth of an immortal line. In contrast to the senescent cell cycle
arrest of wild-type MEFs at passage 9, p21
/
MEFs
continued to proliferate and underwent a dramatic crisis after passage
10 (which precluded further biochemical analysis owing to low cell
numbers). At this stage, the p21
/
culture contained
many large cells, but most of them were smaller than those observed in
wild-type cultures, and they lacked the increase in SA-
-Gal
activity that occurred in the wild-type cultures (data not shown). A
small population of p21
/
MEFs survived the crisis at
p10-11, but even though they resembled senescent cells, they continued
to incorporate BrdU at a high level (Fig. 8C and D), until the culture
eventually died at passage 14. Thus, our data indicate that
p21
/
MEFs do not achieve the cell cycle arrest
characteristic of senescence even though they acquire a senescent
morphology.

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 8.
Sustained pRb hyperphosphorylation, cyclin A- and cyclin
E-associated kinase activity, and BrdU incorporation in senescent
p21 / MEFs. (A) Western blot analysis of cell lysates
prepared from asynchronously growing wild-type (WT) and
p21 / MEF at indicated passages. Passages 9 and 10.5 were terminal for WT and p21 / MEFs, respectively. (B)
Histone H1 kinase activity of cyclin A and cyclin E immunoprecipitates
isolated from the designated cell extracts. (C and D) BrdU
incorporation. Prior to fixation, assynchronously growing wild-type and
p21 / MEFs at the indicated passages were incubated for
45 min in the presence of BrdU. At least 200 cells were scored for BrdU
staining for each passage. Passages 11.5, 12, 13, and 14 present the
21 / MEFs that were "rescued" after a substantial
cell death that occurred after passage 10. (D) Immunofluorescence
microscopy showing BrdU incorporation and DNA staining (Hoechst) of
early- and late-passage wild-type (p6 and p9) and 21 /
(p6 and p13) MEFs. Note the large 21 / MEFs still
incorporating BrdU at passage 13.
|
|
Role of CKI: p21 versus p16.
In terminal-passage wild-type
MEFs, pRb is underphosphorylated, cyclin E-associated kinase activity
is diminished even though cyclin E-Cdk2 complexes are still abundant,
and cyclin A-Cdk2 kinase activity is diminished in conjunction with a
reduction in the amount of cyclin A (Fig. 8A and 9A).
Although these changes parallel the behavior of senescent HDFs, they
are not the result of a comparable age-related increase in p21. Rather,
Western blot analysis revealed no significant difference in p21 between
early-passage and late-passage wild-type MEFs (Fig. 9A), a result in
agreement with the results of Pantoja and Serrano (45).
Nevertheless, indirect immunofluorescence analysis using a p21-specific
antibody showed that most of the senescent wild-type MEFs contained
nuclear p21 (not shown), a finding consistent with their decreased BrdU incorporation (Fig. 8C and D).

View larger version (69K):
[in this window]
[in a new window]
|
FIG. 9.
In late-passage MEFs p16 increase do not block cyclin
D1-Cdk4 association. (A) Western blot analysis of p16, p21, and p27 in
cell extracts prepared from wild-type and p21 / MEFs at
the indicated passages. The 10* and 10.5 values indicate different
passages that preceded crisis. (B) Western blot analysis of p16
immunoprecipitates isolated from cell extracts prepared from wild-type
and p21 / MEFs at the indicated passages. (C) Western
blot analysis of cyclin D1 and cyclin D2 immunoprecipitates isolated
from cell extracts prepared from wild-type and p21 /
MEFs at the indicated passages. In the cyclin D2 immunoprecipitates
isolated from p21 / MEFs, a higher exposure (H.E.) was
necessary to visualize the Cdk4.
|
|
In contrast to p21, the amount of p27 is decreased and the amount of
p16 is increased in late-passage wild-type MEFs (Fig.
9A and B).
However, the increase in p16 had only a small effect,
i.e., there was a
modest increase in Cdk4 and no increase in Cdk6
associated with this
inhibitor in terminal-passage MEFs (Fig.
9B). Consequently, the total
amount of cyclin D1-Cdk4 complexes
remained high (Fig.
9C), although a
moderate decrease of cyclin
D2-Cdk4 complexes occurred (Fig.
9C; in
MEFs we could not detect
cyclin D1-Cdk6 complexes). In
p21
/
MEFs, p16 amounts increased only moderately
between passages
6 and 10 (Fig.
9A and B), and these cells did not
become senescent
in spite of having higher levels of p16 and lower
levels of cyclin
D1- and cyclin D2-Cdk4 complexes than comparably aged
wild-type
MEFs. These observations suggest that in wild-type MEFs, as
in
HDFs, p16 does not play a significant role in mediating the initial
senescent cell cycle arrest; and, furthermore, that extensively
reduced
cyclin D-Cdk complex formation alone is not sufficient
to cause a
senescent cell cycle arrest in cells lacking
p21.
In order to elucidate the mechanism whereby cyclin-Cdk complexes are
inactivated in senescent MEFs, we performed CKI immunodepletion
experiments using anti-p21 and anti-p27 antibodies (as in Fig.
4 and
5). After CKI removal, we compared cyclin A, cyclin E, and
cyclin D1
immunoprecipitates from early- and late-passage wild-type
and
p21
/
MEFs. The results presented in Fig.
10A show that most of the
cyclin A-Cdk2 and cyclin
E-Cdk2 complexes in senescent wild-type
MEFs were removed when p21 was
depleted, whereas the removal of
p27 did not significantly affect these
complexes. These results
imply that association with p21 is primarily
responsible for the
inhibition of the cyclin E- and cyclin A-Cdk2
kinase activity
in senescent MEFs. Likewise, even though the majority
of cyclin
D1-Cdk4 is already associated with p21 in early-passage MEFs,
this association increases further in senescent MEFs (Fig.
10A,
cyclin
D immunoprecipitation). In contrast, p27, rather than p21,
is
associated with about half of the cyclin E-Cdk2 and cyclin
A-Cdk2 in
early-passage p21
/
MEFs. However, the amount of
p27-free cyclin E-Cdk2 and cyclin
A-Cdk2 is the same in early- and
late-passage p21
/
MEFs, a result consistent with the
undiminished activity of these
complexes. Taken together, these results
further support the hypothesis
that p21 is necessary for the senescent
cell cycle arrest, regardless
of whether the net amount of p21 is
increased in the senescent
cells.

View larger version (53K):
[in this window]
[in a new window]
|
FIG. 10.
Cyclin-Cdk complexes increasingly associate with p21 in
late-passage wild-type MEFs. (A) p21 versus p27 immunodepletion. Cell
extracts from early (p5, W.T.; p6, p21 / )- and late (p9,
W.T.; p10, p21 / )-passage MEFs were immunodepleted for
indicated CKI by repeated incubation with appropriate antibody (p21 and
p27). Control extracts ( ) were incubated with protein A beads alone.
After immunodepletion, aliquots of the resulting supernatants were
assessed for the presence of indicated CKI (Sup), whereas the remaining
extracts were used for cyclin A, E, and D1 immunoprecipitation (cyclin
I.P.). The resulting cyclin immunoprecipitates were separated on 12%
SDS-PAGE gels and analyzed for Cdk content. All Western blot signals
were revealed by ECL. Note that owing to low amounts of cyclin D1-Cdk
complexes in p21 / MEFs, we had to show higher-exposure
(H.E.) ECL fluorographs. (B) p21 and p27 immunodepletion: evidence for
CKI-free cyclin D-Cdk4 complexes. The immunodepletion experiment was
carried out as described above except that cell extracts from
replicating wild-type (p7) and p21 / (p8) MEFs were
immunodepleted simultaneously for both p21 and p27. In the latter
cells, only p27-specific antibodies were used. In the upper panel, a
Western blot analysis of the resulting supernatants (Sup) shows that
incubation with p21- and p27-specific antibodies removed virtually all
detectable p21 and p27. In the lower panel, a Western blot analysis of
cyclin D1 and cyclin D2 immunoprecipitates isolated from the extracts
incubated with protein A beads alone ( ) or with anti-CKI mix (+) is
shown. A higher exposure (H.E.) of ECL fluorographs was necessary to
visualize the cyclin D2-associated Cdk4.
|
|
Western blot analysis of cyclin D1 immunoprecipitates following
the immunodepletion in Fig.
10A suggested that CKI-free cyclin
D-Cdk4 complexes may exist. To further substantiate this possibility,
we carried out a simultaneous immunodepletion of both p21 and
p27 (CKI)
in early-passage wild-type and p21
/
MEFs and analyzed
the cyclin D1 and cyclin D2 immunoprecipitates
in the resulting
supernatants. Note that, as far as our results
reveal, immunodepletion
was complete (Fig.
10B, upper panel). Nevertheless,
cyclin D1- and
cyclin D2-Cdk4 complexes could be readily detected
in CKI-depleted
extracts prepared from either wild-type or p21
/
MEFs
(Fig.
10B, lower panel). These results are in agreement with
those
shown in Fig.
5D for cyclin D1 immunoprecipitates in E6
cells and are
consistent with the existence of CKI-free cyclin
D-Cdk
complexes.
 |
DISCUSSION |
The aim of the present study was to determine which physiological
and biochemical events occurring during cellular aging specifically require the presence of p21. To this end, we chose to study HDFs expressing the HPV16 E6 oncogene (55) and MEFs derived from p21
/
mice (8). In addition, we sought to
delineate the respective roles of p21 and p16 in conferring the
senescence-mediated G1 arrest. Even though increasing
evidence suggests that both Cdk inhibitors play important roles in
replicative senescence (7, 52), a recent study has suggested
that p16 could replace p21 in Cdk inactivation in E6 cells
(4). However, the results presented here provide strong
evidence that p21 is still required for inactivation of cyclin E-Cdk2
complex and probably of cyclin D1-Cdk4/Cdk6 complexes at the onset of
senescence in E6 cells with low amounts of p21. In addition, our
results pinpoint the cell cycle events occurring at the transition
between an initial crisis-like phase and the eventual senescence of E6 populations.
Effects of E6 on early-passage cells.
Early- to mid-passage E6
cells exhibit a normally regulated cell cycle and are phenotypically
the same as wild-type cells in their morphology, cell volume, and low
amounts of SA-
-Gal activity and collagenase. However, their content
of p53, p21, and cyclin D1-Cdk4/Cdk6 complexes is reduced relative to
wild-type cells. The reduction in p21 occurs at both the mRNA and
protein level, which is consistent with the role of p53 as a positive transactivator of p21. The reduction in cyclin D1 and its kinase partners is consistent with the hypothesis that p21 stabilizes cyclin
D1-Cdk4/Cdk6 complexes in vivo and thereby also protects each of the
components from degradation (32). Thus, even though expression of HPV-16 E6 can affect the activity or stability of other
proteins beyond p53, e.g., paxillin, CBP/p300, Bak, and a putative GAP
protein (22, 63, 64, 71), the effects on the cell cycle
machinery appear to derive from the decreased amounts of p53 and p21 in
these cells.
Cell cycle deregulation begins in late-passage E6 cells.
In
late-passage populations, the behavior of E6 cells begins to deviate
from that of their wild-type counterparts. There is an accumulation of
abortive mitotic cells due to the lack of p53-mediated G1/S
and G2/M checkpoints that gradually slows down population expansion. Although late-passage E6 cells contain more p21 than early-passage E6 cells, it is still quite low in comparison to wild-type cells, thereby allowing cell cycle progression in spite of an
increasing occurrence of chromosomal aberrations (21). In
addition, serum-stimulated DNA synthesis is increased in these cells
even though pRb hyperphosphorylation is partially decreased. Although
cell cycle regulation is still relatively normal at this stage, it is
not as stringent as in wild-type cells or early-passage E6 cells, e.g.,
cyclin E- and cyclin A-associated kinase activity are downregulated in
serum-deprived quiescent E6 cells and p27 is upregulated, but not as
extensively as in earlier passages. All of these trends become
magnified as the cells reach their terminal passage, where there is no
net increase in cell number.
Lack of pRb hyperphosphorylation despite high cyclin E- and cyclin
A-associated kinase activity.
When E6 cells reach their terminal
passage, a steady cell number is maintained by a balance between cell
death, abortive mitoses, and successful divisions. Replicative E6 cells
in these populations exhibited several characteristics that indicate a
dramatically perturbed cell cycle and altered response to serum. First,
both G1 cyclin expression (D1, E, and A) and cyclin E- and
cyclin A-Cdk2 kinase activity became serum independent, presumably
because the cells failed to upregulate p27 after serum deprivation.
Most importantly, in spite of high cyclin E- and cyclin A-Cdk2
activity, terminal-passage E6 cells accumulate underphosphorylated pRb.
We suggest that this is due to increasing inactivation of cyclin D-Cdk
complexes, because the lack of pRb hyperphosphorylation coincided with
(i) a lack of phosphorylation at a cyclin D1-Cdk4/Cdk6-specific site
(pRb-Ser780), (ii) an accumulation of p21-associated cyclin
D1-Cdk4/Cdk6 complexes, and (iii) reduced cyclin D1-Cdk4/Cdk6 levels.
Alternatively, pRb could be dephosphorylated in these cells as a result
of increasing phosphatase activity, but this event usually occurs at
the M/G1 transition (50). Several recent studies
suggest that cyclin D-mediated phosphorylation of pRb is a prerequisite
for its phosphorylation by cyclin E-Cdk2, owing to a conformational
change induced in pRb by cyclin D-Cdk4/Cdk6 kinases (20, 25,
36). This model strongly supports the interpretation that pRb
hyperphosphorylation fails to take place in terminal-passage E6 cells
because they lack cyclin D-associated kinase activity, even though they
still have abundant cyclin E- and cyclin A-associated kinase activity.
Uncoupling of DNA synthesis from pRb hyperphosphorylation.
The
uncoupling of DNA synthesis from pRb hyperphosphorylation in
terminal-passage E6 cells is quite striking and implies that the
accumulation of underphosphorylated pRb is not sufficient to block DNA
synthesis. An interesting precedent for this was reported by Lukas et
al. (35), who showed that ectopic expression of
constitutively active, nonphosphorylatable pRb (pRb
Cdk)
in human osteosarcoma cells (U2OS) conferred only a transient G1 arrest. The pRb
Cdk-expressing cells
entered S phase but failed to divide and consequently became
increasingly aneuploid, as occurs in E6 cells. Moreover, ectopic
expression of cyclin E, but not cyclin D1, could override the
G1 arrest imposed by either pRb
Cdk or
overexpression of p16, independent of pRb hyperphosphorylation and E2F
activation (34). These data suggested that cyclin E controls
an S-phase-promoting event that is independent of phosphorylation of
pRb. This hypothesis is consistent with recent results showing that
overexpression of cyclin E provokes chromosome instability (59) and with earlier experiments indicating that cyclin E
and cyclin D control different rate-limiting steps in G1
and that cyclin E is essential for the G1/S transition in
Rb-negative as well as Rb-positive cells, whereas cyclin D is not
(34, 43, 48). Thus, our results with terminal-passage E6
cells provide further support for the hypothesis that entry into S
phase can be controlled by high amounts of endogenous cyclin
E-associated kinase activity in the absence of pRb phosphorylation.
Essential role of p21 in the cell cycle arrest in senescent E6
cells.
The eventual senescent cell cycle arrest in E6 cells
coincides with p21-dependent inactivation of cyclin E-Cdk2 complexes and decreased cyclin A expression. This occurs in spite of the fact
that senescent E6 cells contain less p21 than early-passage wild-type
cells. Our data indicate that when E6 cells become senescent, the
majority of their cyclin D1-Cdk4/Cdk6 and cyclin E-Cdk2 complexes are
associated with p21, as is also the case for wild-type senescent cells.
We suggest that this occurs with a smaller amount of p21 in E6 cells
because cyclin D1-Cdk complexes, which normally sequester the vast
majority of p21 (60), are present in low amounts in these
cells regardless of their passage number. In addition, the increase in
p16 that is initiated at end of lifespan contributes to a further
reduction of cyclin D1-Cdk4/Cdk6 complexes and hence renders more p21
available to bind cyclin E-Cdk2. Similarly, even though p27 is at its
lowest level in senescent E6 cells, it may also contribute to
inactivation of the G1 cyclin-Cdk complexes through its
association with a minority of the cyclin D1-Cdk4/Cdk6 complexes and
cyclin E-Cdk2 complexes.
In summary, our studies of the cell cycle machinery in terminal-passage
and senescent E6 cells suggest that p21 plays an essential
role in the
mechanism for the senescent cell cycle arrest despite
the fact that it
is always significantly inferior to the amount
of p21 found in early
passage wild-type HDFs. This conclusion
argues against the simpler
hypothesis that elevated p16 is responsible
for the senescent arrest in
E6 cells but is consistent with the
idea that p16 plays an important
role by reducing the number of
targets for p21 (
4). Although
ectopic expression of active
Raf-1 or p16 alone can induce a
senescence-like state in early-passage
HDFs (
37,
70), this
does not argue that p16 alone is sufficient
because the recipient cells
were not p21
/
but rather E6-expressing HDFs and
therefore had low levels of
p21 to contribute to the arrest process. In
agreement with this
interpretation, ectopic expression of p16 could not
confer G
1 arrest in p21-null colorectal carcinoma cells
(
41). Likewise,
the finding that ectopic expression of Raf
can induce a senescence-like
arrest in early-passage E6 cells does not
necessarily mean that
p21 is not required for senescence because it is
highly likely
that some p21 was present in the E6 cells used in those
experiments.
Similarly, the fact that Li-Fraumeni fibroblasts become
senescent
with significantly decreased amounts of p21 mRNA and protein
does
not mean that p21 is unnecessary for the senescence of HDFs
(
38).
On the other hand, HDFs completely lacking p21
(p21
/
) do not become senescent, implying that p21 is
essential for
that arrest (
7). By carrying out a detailed
analysis of the
cell cycle machinery in p21-deficient E6 cells, we have
shown
that a surprisingly small amount of p21 still plays a key role
in
mediating the senescent cell cycle
arrest.
Uncoupling of the senescence phenotype from the senescent cell
cycle arrest.
Many aspects of the cellular aging process seem to
be unaffected by the expression of E6 and the attendant decreases in
p53 and p21. Consequently, the elevation of p16 and the expression of
the senescence-associated phenotype (altered morphology, increased cell
volume, SA-
-Gal activity, and collagenase) occur at the end of
lifespan in both wild-type HDF and E6 cells even though only the former
cells are senescent at that point. Likewise, elevated p16 and
SA-
-Gal activity are present in late-passage p21
/
HDFs even though these cells do not become senescent (7,
65). Taken together, these results suggest that expression of p16
and the senescence-associated phenotype are regulated by the mitotic clock (e.g., telomere shortening) independently of the senescent cell
cycle arrest.
An increased amount of p21 in later-passage E6 cells is also consistent
with the notion that the basic cellular aging processes
are unchanged
in E6 cells. For example, if the aging process causes
an increase in
the amount of p53 (
31) or in the activity of
p53
(
2), this proportional change should occur equally well
in
E6 cells, albeit starting from a much smaller amount of p53.
Similarly,
if p21 increases owing to increased stabilization of
p21 mRNA
(
11), then the smaller amount of p21 mRNA in E6 cells
should
be stabilized to the same extent. Thus, we suggest that
the modest
increase in p21 in late-passage, terminal-passage,
and senescent E6
cells is consistent with the notion that the
mechanism for the
age-related increase in p21 is intact in these
cells.
p21 is also essential for the senescent cell cycle arrest in
MEFs.
Our studies of wild-type and p21
/
MEFs at
the EOL point provide additional compelling evidence that p21 plays an
essential role in Cdk2 inactivation and inhibition of pRb
phosphorylation. Although wild-type MEFs become senescent
without experiencing an increase in p21 relative to total protein, p21
is responsible for the inhibition of the abundant cyclin E-Cdk2
complexes and remaining cyclin A-Cdk2 complexes in senescent MEFs, just
as it is in senescent HDFs (with high p21) and senescent E6 cells (with low p21). On the other hand, p21
/
MEFs, like
p21
/
HDFs, are unable to achieve a senescent cell cycle
arrest at the EOL point. Rather, cyclin E- and cyclin A-associated
kinase activities remain high in late-passage p21
/
MEFs, as expected if p21 is essential for the inhibition of these complexes. In addition, pRb phosphorylation continues unabated in late
passage p21
/
MEFs, whereas phosphorylation of pRb is
reduced in terminal-passage E6 cells. These results suggest that a
small amount of p21 is needed to block pRb hyperphosphorylation in
cells with high cyclin E and cyclin A kinase activity, presumably
through an inhibitory effect on cyclin D-associated kinase activity.
Nevertheless, as described previously (45), late-passage
p21
/
MEFs have a senescent morphology (but not
SA-
-Gal) when their population expansion ceases (or reaches a
plateau in the case of cultures that eventually immortalize) owing to
crisis-like events. Overall, our data imply that, even though p21 may
be dispensable for some aspects of senescence, its presence is
necessary for inactivation of cyclin-Cdk complexes and that this
function is not replaced by the endogenous activity of p27 and/or p16.
Role of p16 in the senescence of MEFs.
Until recently, the
role of p16 in the senescence of MEFs was ambiguous for several
reasons. First, although p16 increases as MEFs are passaged in culture,
much of the increase occurs in early-passage cells well before
senescence (45, 72; this study). This is in strong
contrast to the situation observed in HDFs, where accumulation of p16
occurs after senescent cell cycle arrest (60). Second,
earlier studies showing that senescence is abrogated in MEFs when the
INK4A gene is altered were complicated by the fact that both p16 and
p19Arf were inactivated (33, 51). Third,
inactivation of p19Arf alone was sufficient to allow escape
from senescence, such that it could account for above results
(29). However, Carnero et al. have now shown that
inactivation of p16 alone is also sufficient to extend the lifespan of
MEFs (12). In addition, reexpression of p16 in immortalized
populations of p16-deficient MEFs caused a loss of proliferative
capacity as long as functional pRb was present. Thus, these data
strongly imply that p16 plays a role in cellular senescence in MEFs.
How can these results be reconciled with our data showing that there is
only a small to moderate decrease in cyclin D-Cdk4 complexes in newly
senescent MEFs compared to MEFs in mid-lifespan? One possibility is
that p16 functions primarily in the maintenance of the senescent cell
cycle arrest but not in its initiation. This hypothesis is consistent
with our previous studies of early and late senescent HDFs, where p16
had little or no effect on the amount of cyclin D1-Cdk4/Cdk6 complexes
in early senescent cells but caused a much greater reduction in those complexes in late senescent cells (60; this study).
Alternatively, because p16 becomes upregulated in early-passage and
still-proliferating MEFs, it may contribute to senescence in these
cells by reducing the amount of cyclin D-Cdk complexes in mid-lifespan,
thus sensitizing the cells to the inhibitory effects of p21 at the EOL.
The absence of a strong increase in p16 in senescent MEFs per se may
partially explain why MEFs arrest less efficiently and immortalize more readily than senescent HDFs.
As mentioned above, abrogation of p19
Arf also promotes the
immortalization of MEFs, and its reexpression in the immortalized
cells
causes the cessation of proliferation (
12,
29). Likewise,
p14
Arf has been shown to be elevated in senescent HDFs, and
its overexpression
in young HDFs causes a senescence-like cell cycle
arrest (
15).
In MEFs, p19
Arf appears to affect
both the p53 and pRb pathways through its inhibitory
effect on MDM2
(
12). Because active MDM2 promotes p53 degradation
and
inhibits pRb activity, these data suggest that elevated levels
of
p14
Arf or p19
Arf may contribute to
senescence through increased p53-mediated transactivation
of p21
and decreased MDM2-mediated inhibition of pRb
activity.
Effects of p21 on cyclin D1-Cdk4/Cdk6 complexes.
The
regulation of cyclin D-associated kinase activity is quite complex, and
many paradoxes remain to be solved. For example, the currently accepted
model emphasizes that in most cases association with p21 or p27 serves
to activate Cdk4 and Cdk6 kinase activity by stabilizing the formation
of cyclin D-Cdk4/Cdk6 complexes (14, 57). Inhibition of
cyclin D-Cdk4/Cdk6 complexes could occur by "titration," in which
association with one molecule of p21 would promote activity, whereas
binding of an additional molecule would be inhibitory (32).
However, in our studies of wild-type and E6 HDFs, there is an
intriguing correlation between the accumulation of underphosphorylated
pRb (Fig. 3A and 5A) and the association of an increased fraction of
the cyclin D1-Cdk4/Cdk6 complexes with p21 (Fig. 5C and D), suggesting
that association with p21 per se may mediate inactivation of these
complexes in vivo.
A further paradox is that neither pRb phosphorylation nor cell cycle
progression seems to be affected in p21
/
p27
/
double null MEFs that fail to assemble detectable
amounts of
cyclin D1-Cdk4/Cdk6 complexes and lack cyclin D1-associated
kinase
activity in an in vitro assay (
14). These results
imply that
if p21- and p27-cyclin D1-Cdk4/Cdk6 complexes are in vivo
pRb
kinases, they may be replaced in some way in the doubly null MEFs.
One possibility suggested by Cheng et al., is that elevated cyclin
E-Cdk2 or cyclin A-Cdk2 activity (increased owing to the lack
of
inhibition by p21 or p27) might compensate for cyclin D-Cdk
activity.
However, our data indicate that in terminal-passage
E6 cells, pRb is
neither hyperphosphorylated nor phosphorylated
at a cyclin D1-specific
site (Ser780), even though these cells
contain fully active cyclin E-
and cyclin A-Cdk2 complexes. Thus,
these data imply that neither cyclin
E-Cdk2 nor cyclin A-Cdk2
activity can replace cyclin D1-Cdk activity in
phosphorylating
pRb in these cells. This conclusion is consistent with
recent
results showing that cyclin D1-mediated pRb phosphorylation is
necessary for subsequent phosphorylation by cyclin E-Cdk2 (
25,
36). On the other hand, most of these results could be reconciled
if one assumes that CKI-free cyclin D-Cdk complexes do exist in
vivo,
albeit in very low levels, as is the case with CKI-free
cyclin E- and
A-Cdk2 complexes (
6,
19,
27,
46,
60).
Indeed, our
immunodepletion experiments carried out in both HDFs
(Fig.
5) and MEFs
(Fig.
10) demonstrate that this indeed may be
the
case.
In conclusion, we hypothesize that the paucity of p21 strongly impedes
the senescent cell cycle arrest in E6 cells and that,
consequently, the
most severely p53- and p21-deficient cells in
the population are
eliminated in the course of aging by events
that resemble crisis
(
9,
21,
54). Even though some aspects
of phenotypic
senescence are expressed in the absence of p21,
we propose that the
senescent cell cycle arrest occurs only in
cells that are able to
inactivate cyclin E-Cdk2 through the action
of
p21.
 |
ACKNOWLEDGMENTS |
We thank Marcel Dorée (CRBM, Montpellier, France), Daniel
Fisher (IGH, Montpellier, France), Annick Péléraux
(Sanofi-Synthelabo, Montpellier, France), and anonymous reviewers
for invaluable comments and critical suggestions. We are also grateful
to Jerry Shay (Dallas, Tex.) for HDF-expressing HPV-16 E6, Tyler
Jacks (Cambridge, Mass.) for p21
/
MEFs, Gilles Ponzio
(INSERM, Nice, France) for anti-cyclin D2 antibody, Thierry Lorca
(CRBM) for anti-Skp2 antibody, Martin Mueller (Heidelberg, Germany) for
anti-E6 antibody, and Pierre Travo (CRBM) for his enthusiastic help
with the time-lapse microscopy. V.D. also acknowledges the skillful
technical help of Delphine Claudet.
This work was supported by a grant from l'Association pour la
Recherche sur le Cancer (ARC-9737; V.D.) and by Public Health Service
grant AG00947 from the National Institute on Aging (G.H.S.).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centre de
Recherche en Biochimie Macromoléculaire (CRBM)-Centre National
de la Recherche Scientifique (CNRS), UPR 1086, 1919, Route de Mende,
34293 Montpellier, France. Phone: (33) 4-67613337. Fax: (33)
4-67521559. E-mail: dulic{at}crbm.cnrs-mop.fr.
 |
REFERENCES |
| 1.
|
Alcorta, D. A.,
Y. Xiong,
D. Phelps,
G. Hannon,
D. Beach, and J. C. Barrett.
1996.
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Proc. Natl. Acad. Sci. USA
93:13742-13747[Abstract/Free Full Text].
|
| 2.
|
Atadja, P.,
H. Wong,
I. Garkavtsev,
C. Veillette, and K. Riabowol.
1995.
Increased activity of p53 in senescing fibroblasts.
Proc. Natl. Acad. Sci. USA
92:8348-8352[Abstract/Free Full Text].
|
| 3.
|
Beijersbergen, R. L.,
L. Carlee,
R. M. Kerkhoven, and R. Bernards.
1995.
Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes.
Genes Dev.
9:1340-1353[Abstract/Free Full Text].
|
| 4.
|
Bond, J. A.,
M. F. Haughton,
J. M. Rowson,
P. J. Smith,
V. Gire,
D. Wynford-Thomas, and F. S. Wyllie.
1999.
Control of replicative life span in human cells: barriers to clonal expansion intermediate between M1 senescence and M2 crisis.
Mol. Cell. Biol.
19:3103-3114[Abstract/Free Full Text].
|
| 5.
|
Bond, J. A.,
F. S. Wyllie, and T. D. Wynford.
1994.
Escape from senescence in human diploid fibroblasts induced directly by mutant p53.
Oncogene
9:1885-1889[Medline].
|
| 6.
|
Bresnahan, W. A.,
I. Boldogh,
T. Ma,
T. Albrecht, and E. A. Thompson.
1996.
Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle.
Cell Growth Differ.
7:1283-1290[Abstract].
|
| 7.
|
Brown, J. P.,
W. Wei, and J. M. Sedivy.
1997.
Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts.
Science
277:831-834[Abstract/Free Full Text].
|
| 8.
|
Brugarolas, J.,
C. Chandrasekaran,
J. I. Gordon,
D. Beach,
T. Jacks, and G. J. Hannon.
1995.
Radiation-induced cell cycle arrest compromised by p21 deficiency.
Nature
377:552-557[CrossRef][Medline].
|
| 9.
|
Bunz, F.,
A. Dutriaux,
C. Lengauer,
T. Waldman,
S. Zhou,
J. P. Brown,
J. M. Sedivy,
K. W. Kinzler, and B. Vogelstein.
1998.
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
Science
282:1497-1501[Abstract/Free Full Text].
|
| 10.
|
Burkhart, B. A.,
D. A. Alcorta,
C. Chiao,
J. S. Isaacs, and J. C. Barrett.
1999.
Two posttranscriptional pathways that regulate p21(Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence.
Exp. Cell. Res.
247:168-175[CrossRef][Medline].
|
| 11.
|
Campisi, J.
1997.
The biology of replicative senescence.
Eur. J. Cancer
33:703-709.
|
| 12.
|
Carnero, A.,
J. D. Hudson,
C. M. Price, and D. H. Beach.
2000.
p16INK4A and p19ARF act in overlapping pathways in cellular immortalization.
Nat. Cell Biol.
2:148-155[CrossRef][Medline].
|
| 13.
|
Carrano, A. C.,
E. Eytan,
A. Hershko, and M. Pagano.
1999.
SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.
Nat. Cell Biol.
1:193-199[CrossRef][Medline].
|
| 14.
|
Cheng, M.,
P. Olivier,
J. A. Diehl,
M. Fero,
M. F. Roussel,
J. M. Roberts, and C. J. Sherr.
1999.
The p21(Cip1) and p27(Kip1) CDK `inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts.
EMBO J.
18:1571-1583[CrossRef][Medline].
|
| 15.
|
Dimri, G. P.,
K. Itahana,
M. Acosta, and J. Campisi.
2000.
Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor.
Mol. Cell. Biol.
20:273-285[Abstract/Free Full Text].
|
| 16.
|
Dimri, G. P.,
X. Lee,
G. Basile,
M. Acosta,
G. Scott,
C. Roskelley,
E. E. Medrano,
M. Linskens,
I. Rubelj,
O. Pereira-Smith, et al.
1995.
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Proc. Natl. Acad. Sci. USA
92:9363-9367[Abstract/Free Full Text].
|
| 17.
|
Duli , V.,
L. F. Drullinger,
E. Lees,
S. I. Reed, and G. H. Stein.
1993.
Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes.
Proc. Natl. Acad. Sci. USA
90:11034-11038[Abstract/Free Full Text].
|
| 18.
|
Duli , V.,
W. K. Kaufmann,
S. J. Wilson,
T. D. Tlsty,
E. Lees,
J. W. Harper,
S. J. Elledge, and S. I. Reed.
1994.
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.
Cell
76:1013-1023[CrossRef][Medline].
|
| 19.
|
Duli , V.,
G. H. Stein,
D. F. Far, and S. I. Reed.
1998.
Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition.
Mol. Cell. Biol.
18:546-557[Abstract/Free Full Text].
|
| 20.
|
Ezhevsky, S. A.,
H. Nagahara,
A. A. Vocero,
D. R. Gius,
M. C. Wei, and S. F. Dowdy.
1997.
Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.
Proc. Natl. Acad. Sci. USA
94:10699-10704[Abstract/Free Full Text].
|
| 21.
|
Filatov, L.,
V. Golubovskaya,
J. C. Hurt,
L. L. Byrd,
J. M. Phillips, and W. K. Kaufmann.
1998.
Chromosomal instability is correlated with telomere erosion and inactivation of G2 checkpoint function in human fibroblasts expressing human papillomavirus type 16 E6 oncoprotein.
Oncogene
16:1825-1838[CrossRef][Medline].
|
| 22.
|
Gao, Q.,
S. Srinivasan,
S. N. Boyer,
D. E. Wazer, and V. Band.
1999.
The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation.
Mol. Cell. Biol.
19:733-744[Abstract/Free Full Text].
|
| 23.
|
Grana, X.,
J. Garriga, and X. Mayol.
1998.
Role of the retinoblastoma protein family, pRb, p107, and p130 in the negative control of cell growth.
Oncogene
17:3365-3383[CrossRef][Medline].
|
| 24.
|
Hara, E.,
R. Smith,
D. Parry,
H. Tahara,
S. Stone, and G. Peters.
1996.
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence.
Mol. Cell. Biol.
16:859-867[Abstract].
|
| 25.
|
Harbour, J. W.,
R. X. Luo,
A. Dei Santi,
A. A. Postigo, and D. C. Dean.
1999.
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.
Cell
98:859-869[CrossRef][Medline].
|
| 26.
|
Hayflick, L.
1965.
The limited in vitro lifetime of human diploid cell strains.
Exp. Cell Res.
37:614-636[CrossRef][Medline].
|
| 27.
|
Hengst, L.,
U. Gopfert,
H. A. Lashuel, and S. I. Reed.
1998.
Complete inhibition of Cdk/cyclin by one molecule of p21(Cip1).
Genes Dev.
12:3882-3888[Abstract/Free Full Text].
|
| 28.
|
Kaelin, W. G., Jr.
1999.
Functions of the retinoblastoma protein.
Bioessays
21:950-958[CrossRef][Medline].
|
| 29.
|
Kamijo, T.,
F. Zindy,
M. F. Roussel,
D. E. Quelle,
J. R. Downing,
R. A. Ashmun,
G. Grosveld, and C. J. Sherr.
1997.
Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.
Cell
91:649-659[CrossRef][Medline].
|
| 30.
|
Kitagawa, M.,
H. Higashi,
H. K. Jung,
I. Suzuki-Takahashi,
M. Ikeda,
K. Tamai,
J. Kato,
K. Segawa,
E. Yoshida,
S. Nishimura, and Y. Taya.
1996.
The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2.
EMBO J.
15:7060-7069[Medline].
|
| 31.
|
Kulju, K. S., and J. M. Lehman.
1995.
Increased p53 protein associated with aging in human diploid fibroblasts.
Exp. Cell Res.
217:336-345[CrossRef][Medline].
|
| 32.
|
LaBaer, J.,
M. D. Garrett,
L. F. Stevenson,
J. M. Slingerland,
C. Sandhu,
H. S. Chou,
A. Fattaey, and E. Harlow.
1997.
New functional activities for the p21 family of CDK inhibitors.
Genes Dev.
11:847-862[Abstract/Free Full Text].
|
| 33.
|
Lloyd, A. C.
2000.
p53: only ARF the story.
Nat. Cell Biol.
2:48-50.
|
| 34.
|
Lukas, J.,
T. Herzinger,
K. Hansen,
M. C. Moroni,
D. Resnitzky,
K. Helin,
S. I. Reed, and J. Bartek.
1997.
Cyclin E-induced S phase without activation of the pRb/E2F pathway.
Genes Dev.
11:1479-1492[Abstract/Free Full Text].
|
| 35.
|
Lukas, J.,
C. S. Sorensen,
C. Lukas,
E. Santoni-Rugiu, and J. Bartek.
1999.
p16INK4a, but not constitutively active pRb, can impose a sustained G1 arrest: molecular mechanisms and implications for oncogenesis.
Oncogene
18:3930-3935[CrossRef][Medline].
|
| 36.
|
Lundberg, A. S., and R. A. Weinberg.
1998.
Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.
Mol. Cell. Biol.
18:753-761[Abstract/Free Full Text].
|
| 37.
|
McConnell, B. B.,
M. Starborg,
S. Brookes, and G. Peters.
1998.
Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts.
Curr. Biol.
8:351-354[CrossRef][Medline].
|
| 38.
|
Medcalf, A. S.,
A. J. Klein-Szanto, and V. J. Cristofalo.
1996.
Expression of p21 is not required for senescence of human fibroblasts.
Cancer Res.
56:4582-4585[Abstract/Free Full Text].
|
| 39.
|
Meyyappan, M.,
H. Wong,
C. Hull, and K. T. Riabowol.
1998.
Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells.
Mol. Cell. Biol.
18:3163-3172[Abstract/Free Full Text].
|
| 40.
|
Millis, A. J.,
M. Hoyle,
H. M. McCue, and H. Martini.
1992.
Differential expression of metalloproteinase and tissue inhibitor of metalloproteinase genes in aged human fibroblasts.
Exp. Cell. Res.
201:373-379[CrossRef][Medline].
|
| 41.
|
Mitra, J.,
C. Y. Dai,
K. Somasundaram,
W. S. El-Deiry,
K. Satyamoorthy,
M. Herlyn, and G. H. Enders.
1999.
Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a).
Mol. Cell. Biol.
19:3916-3928[Abstract/Free Full Text].
|
| 42.
|
Noda, A.,
Y. Ning,
S. F. Venable,
S. O. Pereira, and J. R. Smith.
1994.
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen.
Exp. Cell Res.
211:90-98[CrossRef][Medline].
|
| 43.
|
Ohtsubo, M.,
A. M. Theodoras,
J. Schumacher,
J. M. Roberts, and M. Pagano.
1995.
Human cyclin E, a nuclear protein essential for the G1-to-S phase transition.
Mol. Cell. Biol.
15:2612-2624[Abstract].
|
| 44.
|
Palmero, I.,
B. McConnell,
D. Parry,
S. Brookes,
E. Hara,
S. Bates,
P. Jat, and G. Peters.
1997.
Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status.
Oncogene
15:495-503[CrossRef][Medline].
|
| 45.
|
Pantoja, C., and M. Serrano.
1999.
Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.
Oncogene
18:4974-4982[CrossRef][Medline].
|
| 46.
|
Planas-Silva, M. D., and R. A. Weinberg.
1997.
Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution.
Mol. Cell. Biol.
17:4059-4069[Abstract].
|
| 47.
|
Ponzio, G.,
A. Loubat,
N. Rochet,
L. Turchi,
R. Rezzonico,
D. Farahi Far,
V. Duli , and B. Rossi.
1998.
Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction.
Oncogene
17:1159-1166[CrossRef][Medline].
|
| 48.
|
Resnitzky, D., and S. I. Reed.
1995.
Different roles for cyclins D1 and E in regulation of the G1-to-S transition.
Mol. Cell. Biol.
15:3463-3469[Abstract].
|
| 49.
|
Rogan, E. M.,
T. M. Bryan,
B. Hukku,
K. Maclean,
A. C. Chang,
E. L. Moy,
A. Englezou,
S. G. Warneford,
L. Dalla-Pozza, and R. R. Reddel.
1995.
Alterations in p53 and p16INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts.
Mol. Cell. Biol.
15:4745-4753[Abstract].
|
| 50.
|
Rubin, E.,
S. Tamrakar, and J. W. Ludlow.
1998.
Protein phosphatase type 1, the product of the retinoblastoma susceptibility gene, and cell cycle control.
Front. Biosci.
3:D1209-D1219[Medline].
|
| 51.
|
Serrano, M.,
H. Lee,
L. Chin,
C. Cordon-Cardo,
D. Beach, and R. A. DePinho.
1996.
Role of the INK4a locus in tumor suppression and cell mortality.
Cell
85:27-37[CrossRef][Medline].
|
| 52.
|
Serrano, M.,
A. W. Lin,
M. E. McCurrach,
D. Beach, and S. W. Lowe.
1997.
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.
Cell
88:593-602[CrossRef][Medline].
|
| 53.
|
Shay, J. W.,
S. O. Pereira, and W. E. Wright.
1991.
A role for both RB and p53 in the regulation of human cellular senescence.
Exp. Cell Res.
196:33-39[CrossRef][Medline].
|
| 54.
|
Shay, J. W.,
B. Van der Haegen,
Y. Ying, and W. E. Wright.
1993.
The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen.
Exp. Cell Res.
209:45-52[CrossRef][Medline].
|
| 55.
|
Shay, J. W.,
W. E. Wright,
D. Brasiskyte, and B. van der Haegen.
1993.
E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts.
Oncogene
8:1407-1413[Medline].
|
| 56.
|
Shelton, D. N.,
E. Chang,
P. S. Whittier,
D. Choi, and W. D. Funk.
1999.
Microarray analysis of replicative senescence.
Curr. Biol.
9:939-945[CrossRef][Medline].
|
| 57.
|
Sherr, C. J., and J. M. Roberts.
1999.
CDK inhibitors: positive and negative regulators of G1-phase progression.
Genes Dev.
13:1501-1512[Free Full Text].
|
| 58.
|
Spruck, C. H.,
K. A. Won, and S. I. Reed.
1999.
Deregulated cyclin E induces chromosome instability.
Nature
401:297-300[CrossRef][Medline].
|
| 59.
|
Stein, G. H.,
M. Beeson, and L. Gordon.
1990.
Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts.
Science
249:666-669[Abstract/Free Full Text].
|
| 60.
|
Stein, G. H.,
L. F. Drullinger,
A. Soulard, and V. Duli .
1999.
Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
Mol. Cell. Biol.
19:2109-2117[Abstract/Free Full Text].
|
| 61.
|
Stein, G. H., and V. Duli .
1995.
Origins of G1 arrest in senescent human fibroblasts.
Bioessays
17:537-543[CrossRef][Medline].
|
| 62.
|
Sutterluty, H.,
E. Chatelain,
A. Marti,
C. Wirbelauer,
M. Senften,
U. Muller, and W. Krek.
1999.
p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells.
Nat. Cell Biol.
1:207-214[CrossRef][Medline].
|
| 63.
|
Thomas, M., and L. Banks.
1999.
Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types.
J. Gen. Virol.
80:1513-1517[Abstract].
|
| 64.
|
Tong, X.,
R. Salgia,
J. L. Li,
J. D. Griffin, and P. M. Howley.
1997.
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase.
J. Biol. Chem.
272:33373-33376[Abstract/Free Full Text].
|
| 65.
|
Wei, W., and J. M. Sedivy.
1999.
Differentiation between senescence (M1) and crisis (M2) in human fibroblast cultures.
Exp. Cell Res.
253:519-522[CrossRef][Medline].
|
| 66.
|
Xiao, Z. X.,
D. Ginsberg,
M. Ewen, and D. M. Livingston.
1996.
Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases.
Proc. Natl. Acad. Sci. USA
93:4633-4637[Abstract/Free Full Text].
|
| 67.
|
Xiong, Y.,
D. Kuppuswamy,
Y. Li,
E. M. Livanos,
M. Hixon,
A. White,
D. Beach, and T. D. Tlsty.
1996.
Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation.
J. Virol.
70:999-1008[Abstract].
|
| 68.
|
Yu, Z. K.,
J. L. Gervais, and H. Zhang.
1998.
Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins.
Proc. Natl. Acad. Sci. USA
95:11324-11329[Abstract/Free Full Text].
|
| 69.
|
Zhang, H.,
R. Kobayashi,
K. Galaktionov, and D. Beach.
1995.
p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase.
Cell
82:915-925[CrossRef][Medline].
|
| 70.
|
Zhu, J.,
D. Woods,
M. McMahon, and J. M. Bishop.
1998.
Senescence of human fibroblasts induced by oncogenic Raf.
Genes Dev.
12:2997-3007[Abstract/Free Full Text].
|
| 71.
|
Zimmermann, H.,
R. Degenkolbe,
H. U. Bernard, and M. J. O'Connor.
1999.
The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.
J. Virol.
73:6209-6219[Abstract/Free Full Text].
|
| 72.
|
Zindy, F.,
D. E. Quelle,
M. F. Roussel, and C. J. Sherr.
1997.
Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging.
Oncogene
15:203-211[CrossRef][Medline].
|
Molecular and Cellular Biology, September 2000, p. 6741-6754, Vol. 20, No. 18
0270-7306/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lotan, T., Hickson, J., Souris, J., Huo, D., Taylor, J., Li, T., Otto, K., Yamada, S. D., Macleod, K., Rinker-Schaeffer, C. W.
(2008). c-Jun NH2-Terminal Kinase Activating Kinase 1/Mitogen-Activated Protein Kinase Kinase 4-Mediated Inhibition of SKOV3ip.1 Ovarian Cancer Metastasis Involves Growth Arrest and p21 Up-regulation. Cancer Res.
68: 2166-2175
[Abstract]
[Full Text]
-
Ruas, M., Gregory, F., Jones, R., Poolman, R., Starborg, M., Rowe, J., Brookes, S., Peters, G.
(2007). CDK4 and CDK6 Delay Senescence by Kinase-Dependent and p16INK4a-Independent Mechanisms. Mol. Cell. Biol.
27: 4273-4282
[Abstract]
[Full Text]
-
Ksiazek, K., Piwocka, K., Brzezinska, A., Sikora, E., Zabel, M., Breborowicz, A., Jorres, A., Witowski, J.
(2006). Early loss of proliferative potential of human peritoneal mesothelial cells in culture: the role of p16INK4a-mediated premature senescence. J. Appl. Physiol.
100: 988-995
[Abstract]
[Full Text]
-
Sarsour, E. H., Agarwal, M., Pandita, T. K., Oberley, L. W., Goswami, P. C.
(2005). Manganese Superoxide Dismutase Protects the Proliferative Capacity of Confluent Normal Human Fibroblasts. J. Biol. Chem.
280: 18033-18041
[Abstract]
[Full Text]
-
Alexander, K., Yang, H.-S., Hinds, P. W.
(2004). Cellular Senescence Requires CDK5 Repression of Rac1 Activity. Mol. Cell. Biol.
24: 2808-2819
[Abstract]
[Full Text]
-
Alexander, K., Yang, H.-S., Hinds, P. W.
(2003). pRb Inactivation in Senescent Cells Leads to an E2F-Dependent Apoptosis Requiring p73. Mol Cancer Res
1: 716-728
[Abstract]
[Full Text]
-
Davis, T., Singhrao, S. K., Wyllie, F. S., Haughton, M. F., Smith, P. J., Wiltshire, M., Wynford-Thomas, D., Jones, C. J., Faragher, R. G. A., Kipling, D.
(2003). Telomere-based proliferative lifespan barriers in Werner-syndrome fibroblasts involve both p53-dependent and p53-independent mechanisms. J. Cell Sci.
116: 1349-1357
[Abstract]
[Full Text]
-
Itahana, K., Zou, Y., Itahana, Y., Martinez, J.-L., Beausejour, C., Jacobs, J. J. L., van Lohuizen, M., Band, V., Campisi, J., Dimri, G. P.
(2003). Control of the Replicative Life Span of Human Fibroblasts by p16 and the Polycomb Protein Bmi-1. Mol. Cell. Biol.
23: 389-401
[Abstract]
[Full Text]
-
Itahana, K., Dimri, G. P., Hara, E., Itahana, Y., Zou, Y., Desprez, P.-Y., Campisi, J.
(2002). A Role for p53 in Maintaining and Establishing the Quiescence Growth Arrest in Human Cells. J. Biol. Chem.
277: 18206-18214
[Abstract]
[Full Text]
-
Alexander, K., Hinds, P. W.
(2001). Requirement for p27KIP1 in Retinoblastoma Protein-Mediated Senescence. Mol. Cell. Biol.
21: 3616-3631
[Abstract]
[Full Text]